Reading File

analyse_media

This is a Third Prof. MBBS Part-II (New Scheme) Main Exam, March 2026 question paper. I can see all the questions clearly. Let me know which questions you'd like answered in detail - I can cover any or all of them.

Paper Extracted - III MBBS Part-II Main Exam, March 2026

Q.4 Write briefly on any five of the following. (5 x 2 = 10)

a) Causes of Acute Kidney Injury
b) Blood pressure management in Acute Ischemic Stroke
c) Treatment of Chronic Hepatitis C
d) Jones criteria for Acute Rheumatic Fever
e) Procedure of Lumbar Puncture
f) CSF findings in TB Meningitis

Q.5 Write briefly on any three of the following. (3 x 5 = 15)

a) Chronic Myeloid Leukemia
b) Peripheral blood film examination and its uses
c) Etiology of Portal Hypertension
d) Management of TB with HIV

Section B

Q.6 (4 x 5 = 20)

A 60-year-old female patient, a known case of hypothyroidism not on treatment since 6 months, came to emergency with complaints of altered mentation since 2 days. Pulse rate: 44/min, BP: 80/60 mmHg, RR: 9/min, Temperature: 94°F. Skin was dry and cold. ECG showed low voltage QRS complexes with sinus bradycardia.

a) What is the most probable diagnosis?
b) Describe the various laboratory abnormalities seen in this condition.
c) Describe management of this patient.
d) Write short note on thyroid function tests.

Q.7 Write briefly on any five of the following. (5 x 2 = 10)

a) Tropical Splenomegaly Syndrome
b) Cluster Headache
c) Treatment of H. Pylori infection
d) Posterior circulation of the brain
e) Clinical features of Subacute Combined Degeneration of Spinal Cord
f) Tropical Sprue

Q.8 Write short notes. (4 x 5 = 20)

a) Informed Consent
b) Complications of Diabetes Mellitus
c) CREST Syndrome
d) Anemia due to Gastrointestinal Bleeding

Which questions would you like me to answer in detail? I can provide model answers for exam preparation using authoritative medical textbook content.

Answer all of these questions

Finding Sources

Here are comprehensive model answers for all questions from the III MBBS Part-II Main Exam, March 2026:

III MBBS Part-II Main Exam - Complete Model Answers

Q.4 Write Briefly on Any Five

a) Causes of Acute Kidney Injury (AKI)

AKI is classified into three categories - Prerenal, Renal (Intrinsic), and Postrenal.

Prerenal (most common, ~55%):

Hypovolemia: hemorrhage, burns, vomiting, diarrhea, diuretics
Reduced cardiac output: heart failure, cardiogenic shock, cardiac tamponade
Systemic vasodilation: sepsis, anaphylaxis
Hepatorenal syndrome

Renal (Intrinsic, ~40%):

Vascular: renal artery thrombosis/stenosis, vasculitis, TTP/HUS
Glomerular: acute glomerulonephritis, rapidly progressive GN
Tubular: Acute Tubular Necrosis (ATN) - most common intrinsic cause; from ischemia or nephrotoxins (aminoglycosides, NSAIDs, contrast dye, myoglobinuria)
Interstitial: Acute Interstitial Nephritis (AIN) - drug-induced (penicillins, NSAIDs), infections

Postrenal (~5%):

Urethral obstruction: BPH, urethral stricture
Bilateral ureteric obstruction: stones, retroperitoneal fibrosis, tumor
Bladder outlet obstruction: neurogenic bladder, anticholinergics

RIFLE/KDIGO Criteria for Diagnosis: Rise in serum creatinine ≥0.3 mg/dL within 48 hours, or ≥1.5x baseline within 7 days, or urine output <0.5 mL/kg/hr for >6 hours.

b) Blood Pressure Management in Acute Ischemic Stroke

Blood pressure management in acute ischemic stroke depends on whether the patient is a candidate for thrombolysis (tPA/alteplase):

If eligible for thrombolysis (IV tPA):

BP must be brought to <185/110 mmHg before starting tPA
Maintain BP <180/105 mmHg for at least 24 hours after tPA
Use IV labetalol (10-20 mg bolus) or nicardipine infusion

If NOT eligible for thrombolysis:

Permissive hypertension is allowed up to 220/120 mmHg for the first 24-48 hours
This maintains collateral perfusion to the ischemic penumbra
Only treat if BP >220/120 mmHg or if there is hypertensive encephalopathy, aortic dissection, or acute MI
Lower BP by no more than 15% in the first 24 hours

Hypotension should be aggressively avoided as it worsens ischemia.

Long term: Antihypertensive therapy is initiated after 24-48 hours of stability, targeting BP <130/80 mmHg for secondary prevention.

c) Treatment of Chronic Hepatitis C

The goal is sustained virological response (SVR = undetectable HCV RNA 12 weeks after treatment end), which is considered a cure.

Direct-Acting Antivirals (DAAs) - Current Standard of Care:

Regimen	Genotype	Duration
Sofosbuvir + Velpatasvir (Epclusa)	Pan-genotypic (1-6)	12 weeks
Glecaprevir + Pibrentasvir (Mavyret)	Pan-genotypic	8-12 weeks
Sofosbuvir + Ledipasvir (Harvoni)	Genotype 1, 4, 5, 6	12 weeks
Sofosbuvir + Daclatasvir	Genotype 3	12 weeks

Pre-treatment workup: HCV genotype, viral load (RNA quantification), liver fibrosis assessment (fibroscan/biopsy), HBV/HIV co-infection screening, renal function.

SVR rates: >95% with modern DAA regimens.

Note: Interferon-based therapy is now largely obsolete.

d) Jones Criteria for Acute Rheumatic Fever (ARF)

ARF follows Group A beta-hemolytic Streptococcal (GABHS) pharyngitis. Diagnosis requires:

Evidence of prior streptococcal infection (positive throat culture/ASO titer/anti-DNase B) PLUS
2 Major criteria OR 1 Major + 2 Minor criteria

Major Criteria (JONES):

J - Joints (Migratory polyarthritis) - most common
O - (c)Orea (Sydenham's chorea) - involuntary movements
N - Nodules (Subcutaneous nodules)
E - Erythema marginatum (ring-shaped skin rash)
S - Carditis (pancarditis) - most serious; causes mitral regurgitation

Minor Criteria:

Fever (>38.5°C)
Elevated ESR (>60 mm/hr) or CRP
Prolonged PR interval on ECG
Elevated WBC
Arthralgia (only if arthritis not already a major criterion)

Note (2015 AHA Revised Criteria): For high-risk populations, monoarthritis or polyarthralgia may qualify as major criterion.

e) Procedure of Lumbar Puncture (LP)

Indications: Meningitis, subarachnoid hemorrhage, TB meningitis, cryptococcal meningitis, GBS, intrathecal drug therapy.

Contraindications: Raised ICP with papilledema, coagulopathy (INR>1.5, platelets <50,000), local skin infection, spinal cord compression.

Position: Left lateral decubent (fetal position) OR seated and leaning forward.

Landmark: L3-L4 or L4-L5 interspace (below the conus medullaris, which ends at L1-L2).

Procedure:

Patient positioned; iliac crests identified (Tuffier's line = L4 spinous process)
Skin cleaned with betadine/chlorhexidine; sterile drape applied
Local anesthesia: 1-2% lidocaine injected subcutaneously
Lumbar puncture needle (22G, with stylet) inserted at midline, directed slightly cranially
Needle advanced through skin → subcutaneous tissue → supraspinous ligament → interspinous ligament → ligamentum flavum → epidural space → dura mater → subarachnoid space
Stylet removed; CSF drip confirms correct placement
Opening pressure measured with manometer (normal: 70-180 mm H2O)
3-4 tubes of CSF collected (cell count, protein/glucose, culture, special tests)
Stylet replaced; needle withdrawn; dressing applied

Post-LP: Lie flat 4-6 hours; hydrate well to prevent post-LP headache.

f) CSF Findings in TB Meningitis

TB meningitis produces a characteristic CSF profile:

Parameter	TB Meningitis
Appearance	Clear / slightly turbid (forms a cobweb clot on standing)
Opening pressure	Elevated (200-400 mm H2O)
Cells	100-500 cells/µL; predominantly lymphocytes (lymphocytic pleocytosis)
Protein	Markedly elevated: 100-500 mg/dL (may be >500 in advanced cases)
Glucose	Low (<45 mg/dL); CSF:Serum glucose ratio <0.5
Chloride	Reduced
AFB smear	Positive in only 10-40%
Culture (gold standard)	Lowenstein-Jensen medium; takes 6-8 weeks
ADA (Adenosine deaminase)	Elevated (>10 U/L) - useful marker
Xpert MTB/RIF	Rapid molecular diagnosis

Classic triad on imaging: Basal meningeal enhancement, hydrocephalus, and cerebral infarction.

Q.5 Write Briefly on Any Three

a) Chronic Myeloid Leukemia (CML)

Definition: Myeloproliferative neoplasm of a pluripotent stem cell, characterized by the BCR-ABL1 fusion oncogene from the Philadelphia chromosome t(9;22)(q34;q11).

Pathogenesis: Translocation of ABL1 gene (chromosome 9) to BCR gene (chromosome 22) → BCR-ABL1 fusion protein with constitutively active tyrosine kinase → uncontrolled myeloid proliferation.

Phases:

Chronic phase (CP): Most at diagnosis; 90% cells differentiate normally
Accelerated phase (AP): Blasts 10-19%; increasing basophilia
Blast crisis (BC): Blasts ≥20%; acute leukemia-like picture (myeloid 70%, lymphoid 30%)

Clinical Features:

Insidious onset; fatigue, weight loss, night sweats
Massive splenomegaly (hallmark) - often filling the abdomen
Hepatomegaly, sternal tenderness
Hyperviscosity symptoms

Investigations:

CBC: Marked leukocytosis (often >100,000/µL) with entire myeloid series
Blood film: Myelocytes, metamyelocytes, basophilia, eosinophilia - "left shift"
Low Leukocyte Alkaline Phosphatase (LAP) score (differentiates from leukemoid reaction)
Philadelphia chromosome on cytogenetics; BCR-ABL1 by FISH/PCR
Bone marrow: Hypercellular with myeloid hyperplasia

Treatment:

Tyrosine Kinase Inhibitors (TKIs) - first line: Imatinib (Gleevec) 400 mg/day; 2nd gen: Dasatinib, Nilotinib (more potent, used in resistance)
Monitoring: BCR-ABL1 PCR at 3, 6, 12 months (aim for major molecular response)
Stem cell transplant: Reserved for blast crisis or TKI failure
Complete cytogenetic response (CCyR) at 12 months = good prognosis

b) Peripheral Blood Film Examination and its Uses

Technique:

Thin smear of peripheral blood on glass slide, dried, stained with Leishman or Giemsa stain
Examined under oil immersion (100x) in the "counting zone" (monolayer area)

Uses and Findings:

1. Red Cell Abnormalities:

Microcytic hypochromic: Iron deficiency anemia, thalassemia
Macrocytic: Megaloblastic anemia (B12/folate deficiency), liver disease
Sickle cells: Sickle cell anemia
Target cells: Liver disease, thalassemia, iron deficiency
Spherocytes: Hereditary spherocytosis, autoimmune hemolysis
Schistocytes/helmet cells: TTP, HUS, DIC, microangiopathic hemolysis
Malarial parasites: Plasmodium species identified by morphology

2. White Cell Abnormalities:

Left shift (bands, metamyelocytes): Bacterial infection, CML
Hypersegmented neutrophils: Megaloblastic anemia
Blast cells: Acute leukemia
Auer rods in blasts: AML specifically
Smudge cells: CLL (hallmark)
Atypical lymphocytes: Infectious mononucleosis (EBV)
Full myeloid series: CML

3. Platelet Abnormalities:

Thrombocytopenia, giant platelets (ITP, MDS)

4. Other:

Rouleaux formation: Multiple myeloma, chronic inflammation
Microfilariae: Filariasis

c) Etiology of Portal Hypertension

Portal hypertension is defined as portal vein pressure >10 mmHg (normal 5-10 mmHg). Clinically significant at >12 mmHg.

Classification by site of obstruction:

1. Prehepatic (pre-sinusoidal):

Portal vein thrombosis (most common prehepatic cause)
Splenic vein thrombosis
Increased portal blood flow (AV fistula, splenomegaly)
Schistosomiasis (presinusoidal due to portal granulomas)

2. Intrahepatic:

Presinusoidal: Schistosomiasis, primary biliary cirrhosis, sarcoidosis, congenital hepatic fibrosis
Sinusoidal (most common overall): Cirrhosis (viral hepatitis B & C, alcoholic, NASH, autoimmune)
Postsinusoidal: Veno-occlusive disease (sinusoidal obstruction syndrome), alcoholic hepatitis

3. Post-hepatic (post-sinusoidal):

Budd-Chiari syndrome (hepatic vein thrombosis)
Constrictive pericarditis
Right heart failure / tricuspid regurgitation
Inferior vena cava obstruction

Consequences: Esophageal/gastric varices, splenomegaly, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, caput medusae.

d) Management of TB with HIV

Key Principles:

Treat both TB and HIV; TB takes priority (start TB therapy first)
ART initiation timing depends on CD4 count
Drug-drug interactions (especially rifampicin with ART) require careful drug selection

Anti-TB Treatment:

Standard regimen: 2HRZE / 4HR (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol for 2 months; then Isoniazid + Rifampicin for 4 months)
Total duration: 6 months (same as HIV-negative patients)
Pyridoxine (Vitamin B6) 25-50 mg/day given to all (prevents INH neuropathy)

ART Initiation Timing:

CD4 < 50 cells/µL: Start ART within 2 weeks of starting TB treatment
CD4 ≥ 50 cells/µL: Start ART within 8 weeks of starting TB treatment
TB meningitis: Start ART after 4-8 weeks (earlier ART increases IRIS risk in CNS TB)

ART Drug Choice with Rifampicin:

Rifampicin is a potent CYP3A4 inducer - reduces levels of most PIs
Preferred ART: Efavirenz 600 mg + 2 NRTIs (TDF + 3TC or FTC)
Alternatives: Dolutegravir 50 mg BD (double dose) + 2 NRTIs

IRIS (Immune Reconstitution Inflammatory Syndrome):

Paradoxical worsening after ART initiation (fever, lymphadenopathy, worsening infiltrates)
Managed with NSAIDs or steroids; do NOT stop ART or anti-TB

Cotrimoxazole prophylaxis for all HIV+TB co-infected patients.

Q.6 - Clinical Case: Myxedema Coma

a) Most Probable Diagnosis

Myxedema Coma

This is supported by:

Known hypothyroidism, not on treatment for 6 months
Altered mentation (coma/stupor)
Hypothermia: 94°F (34.4°C) - hallmark finding
Bradycardia: HR 44/min
Hypotension: BP 80/60 mmHg
Bradypnea: RR 9/min (hypoventilation)
Dry, cold skin
ECG: Low voltage QRS + sinus bradycardia

Precipitating factors to consider: Infections (most common), cold exposure, surgery, sedatives/opioids, trauma, non-compliance with thyroid medications.

b) Laboratory Abnormalities in Myxedema Coma

Thyroid Function:

TSH: Markedly elevated (>100 mIU/L in primary hypothyroidism)
Free T4 and T3: Markedly low
(Low TSH + low T4 = central/secondary hypothyroidism)

Metabolic:

Hyponatremia (dilutional - due to SIADH-like syndrome, impaired free water excretion) - most common electrolyte abnormality
Hypoglycemia (reduced gluconeogenesis)
Hypercalcemia (occasionally)

Hematological:

Normocytic normochromic anemia (or macrocytic if B12 deficiency co-exists)
Elevated bleeding time (coagulopathy)

Biochemical:

Elevated CPK (creatine kinase) - from myopathy
Elevated LDH
Elevated AST/ALT (mild hepatic dysfunction)
Hypercholesterolemia, hypertriglyceridemia
Elevated serum creatinine (reduced GFR)

ABG:

Hypoxemia (PaO2 low)
Hypercapnia (CO2 retention - type 2 respiratory failure due to hypoventilation)
Respiratory acidosis

ECG:

Sinus bradycardia
Low voltage QRS complexes (due to pericardial effusion/myxedema of myocardium)
Prolonged QT interval
Flat or inverted T waves

c) Management of Myxedema Coma

Myxedema coma carries 25-60% mortality. Management in ICU setting:

1. Airway & Breathing:

Intubation and mechanical ventilation if GCS <8 or respiratory failure
Supplemental O2

2. Circulation:

IV fluids cautiously (risk of dilutional hyponatremia)
Vasopressors if refractory hypotension

3. Thyroid Hormone Replacement:

IV Levothyroxine (T4): Loading dose 200-400 mcg IV, then 50-100 mcg IV daily
Some add IV Liothyronine (T3): 5-20 mcg IV every 8-12 hours (faster acting, but risk of cardiac arrhythmias)
Oral therapy once patient can swallow

4. Glucocorticoids (MANDATORY before thyroid hormone):

Hydrocortisone 100 mg IV every 8 hours - given BEFORE levothyroxine
Rationale: Hypothyroidism may mask coexisting adrenal insufficiency (Schmidt syndrome); thyroid hormone replacement without steroids can precipitate Addisonian crisis
Continue until adrenal insufficiency excluded by 8 AM cortisol/ACTH stimulation test

5. Treat Hyponatremia:

Fluid restriction; hypertonic saline (3% NaCl) if Na <120 mEq/L or severe symptoms
Correct no faster than 8-10 mEq/L per day (prevent osmotic demyelination)

6. Treat Hypoglycemia:

IV Dextrose

7. Treat Hypothermia:

Passive external rewarming (blankets); avoid active heating (causes vasodilation and hypotension)
Target temperature correction

8. Treat Precipitating Cause:

Broad-spectrum antibiotics if infection suspected

9. Monitoring:

Continuous cardiac monitoring, temperature, glucose, electrolytes

d) Thyroid Function Tests (TFTs)

Hormones measured:

Test	Normal Value	Notes
TSH (Thyroid Stimulating Hormone)	0.4 - 4.0 mIU/L	Most sensitive test for thyroid dysfunction; first-line test
Free T4 (fT4)	0.8 - 1.8 ng/dL	Unbound T4; reflects active hormone
Free T3 (fT3)	2.3 - 4.2 pg/mL	More biologically active
Total T4	5-12 µg/dL	Affected by binding proteins
Total T3	80-200 ng/dL	Affected by binding proteins

Interpretation:

Pattern	TSH	fT4	Diagnosis
Primary hypothyroidism	High ↑	Low ↓	Hashimoto's, post-ablation
Primary hyperthyroidism	Low ↓	High ↑	Graves', toxic nodule
Secondary hypothyroidism	Low/Normal	Low ↓	Pituitary failure
Subclinical hypothyroidism	High ↑	Normal	Early disease
Subclinical hyperthyroidism	Low ↓	Normal	Early Graves'
Sick euthyroid syndrome	Normal/Low	Normal/Low	Critical illness

Additional Tests:

Anti-TPO antibodies (anti-thyroid peroxidase): Hashimoto's thyroiditis
Anti-TSH receptor antibodies (TRAb/TSI): Graves' disease
Anti-thyroglobulin antibodies: Hashimoto's
Thyroglobulin: Monitoring differentiated thyroid cancer after thyroidectomy
Calcitonin: Medullary thyroid carcinoma
Radioactive iodine uptake (RAIU): Distinguishes Graves' (high uptake) from thyroiditis (low uptake)
Thyroid ultrasound: Nodule characterization

Q.7 Write Briefly on Any Five

a) Tropical Splenomegaly Syndrome (TSS)

(Also called Hyperreactive Malarial Splenomegaly - HMS)

Definition: Abnormal immunological response to repeated malarial infections, causing massive splenomegaly without active parasitemia.

Pathogenesis: Repeated Plasmodium falciparum infection → dysregulated B-cell response → polyclonal IgM elevation → IgM-IgG immune complexes → Kupffer cell stimulation in liver → splenomegaly.

Clinical Features:

Massive, painless splenomegaly (often crossing midline)
Hypersplenism: anemia, leucopenia, thrombocytopenia
Abdominal discomfort/dragging pain
Frequent malarial episodes in history

Investigations:

Markedly elevated serum IgM (>2 SD above normal)
Malarial antibodies (high titer) - positive
Peripheral blood: pancytopenia
Blood film: No malarial parasites
Bone marrow: Reactive changes, lymphoid proliferation
Liver biopsy: Sinusoidal lymphocytosis (Kupffer cell hyperplasia)

Treatment:

Long-term antimalarial prophylaxis: Proguanil 200 mg/day OR chloroquine (where sensitive) - continued for at least 3-5 years
Splenomegaly regresses with treatment

b) Cluster Headache

Definition: Most severe form of primary headache; unilateral, periorbital, excruciating pain in clusters lasting weeks to months.

Epidemiology: More common in men (5:1 male:female ratio); age 20-40 years; often associated with smoking and alcohol.

Clinical Features:

Severe, unilateral, periorbital/temporal pain ("suicide headache")
Duration: 15 minutes to 3 hours (typically 45-90 min)
Frequency: 1-8 attacks per day, occurring in "clusters" (weeks to months), then remission
Strictly unilateral (same side in a cluster)
Associated ipsilateral autonomic features: lacrimation, conjunctival injection, rhinorrhea/nasal congestion, miosis, ptosis, facial flushing, eyelid edema
Restlessness/agitation (patient paces - unlike migraine patient who prefers lying still)

Diagnosis: Clinical (ICHD-3 criteria); MRI brain to exclude secondary causes.

Treatment:

Acute attack:

100% O2 inhalation at 12-15 L/min for 15-20 minutes via non-rebreather mask (most effective, first-line)
Subcutaneous Sumatriptan 6 mg (fastest acting triptan) OR intranasal
Intranasal zolmitriptan/lidocaine
Avoid oral analgesics (too slow)

Prevention (for cluster period):

Verapamil 240-960 mg/day (drug of choice for prophylaxis)
Short-term: Prednisolone tapering course to break the cluster
Lithium carbonate (for chronic cluster)
Topiramate, melatonin

c) Treatment of H. Pylori Infection

Indications for Eradication: Peptic ulcer disease (PUD), gastric MALT lymphoma, early gastric cancer resection, functional dyspepsia, first-degree relatives of gastric cancer, long-term NSAIDs/aspirin users, iron deficiency anemia, ITP.

Regimens:

1. Standard Triple Therapy (14 days - preferred):

PPI (standard dose) + Clarithromycin 500 mg + Amoxicillin 1 g - all BD
Eradication rate: ~70-85% (declining due to clarithromycin resistance)

2. Bismuth Quadruple Therapy (14 days - preferred in high clarithromycin resistance areas):

PPI BD + Bismuth subcitrate 120 mg QID + Tetracycline 500 mg QID + Metronidazole 500 mg TID
Eradication rate: ~85-90%

3. Concomitant Therapy (14 days):

PPI + Clarithromycin + Amoxicillin + Metronidazole - all BD (4 drugs simultaneously)
Eradication rate: ~85%

4. Sequential Therapy (10 days):

Days 1-5: PPI + Amoxicillin; Days 6-10: PPI + Clarithromycin + Metronidazole

5. Levofloxacin Triple (salvage/rescue therapy after failure):

PPI + Levofloxacin + Amoxicillin BD x 14 days

Confirmation of Eradication:

Urea breath test (UBT) - gold standard non-invasive test, at least 4 weeks after treatment
Fecal antigen test

d) Posterior Circulation of the Brain

The posterior circulation (vertebrobasilar system) supplies the brainstem, cerebellum, thalamus, and occipital lobes.

Vessels:

Vertebral arteries (from subclavian arteries) → join at pontomedullary junction to form:
Basilar artery (runs along anterior pons) → bifurcates into:
Posterior Cerebral Arteries (PCAs) (bilateral)

Branches and territories:

PICA (Posterior Inferior Cerebellar Artery) - from vertebral artery: Lateral medulla, posterior inferior cerebellum; occlusion = Wallenberg syndrome (lateral medullary syndrome)
AICA (Anterior Inferior Cerebellar Artery) - from lower basilar: Anterior inferior cerebellum, lateral lower pons
SCA (Superior Cerebellar Artery) - from upper basilar: Superior cerebellum, upper pons
PCA: Occipital lobe (primary visual cortex), medial temporal lobe, thalamus

Posterior Circulation Stroke (Vertebrobasilar Insufficiency) Features:

"5 D's": Dizziness, Diplopia, Dysphagia, Dysarthria, Deficits (motor/sensory)
Cerebellar signs: Ataxia, nystagmus
Crossed deficits (ipsilateral cranial nerve + contralateral body)
Occipital stroke: Homonymous hemianopia
Basilar artery occlusion: "Locked-in syndrome"

e) Clinical Features of Subacute Combined Degeneration of Spinal Cord (SACD)

Definition: Degeneration of posterior and lateral columns of the spinal cord due to Vitamin B12 (cobalamin) deficiency.

Pathogenesis: B12 deficiency → impaired myelin synthesis (required for methylmalonyl-CoA conversion and methionine synthesis) → demyelination of dorsal columns + corticospinal tracts.

Causes of B12 Deficiency: Pernicious anemia (most common - anti-intrinsic factor antibodies), strict vegetarian diet, gastrectomy, terminal ileal disease (Crohn's), fish tapeworm, N2O anesthesia abuse, metformin use.

Clinical Features (triad):

Posterior column involvement (earliest and most prominent):
- Tingling, numbness, paresthesias in hands and feet (glove-and-stocking)
- Loss of vibration sense and proprioception
- Sensory ataxia (positive Romberg's sign)
- Pseudoathetosis (abnormal involuntary movements of outstretched fingers due to proprioceptive loss)
Lateral column (corticospinal tract) involvement:
- Weakness of legs → spastic paraparesis
- Hyperreflexia, extensor plantar response (Babinski sign)
- Urgency of micturition, constipation (late)
Psychiatric/Cerebral involvement:
- "Megaloblastic madness": depression, psychosis, dementia, memory loss, irritability
- Optic neuropathy (rare): visual loss

Other features: Macrocytic megaloblastic anemia, glossitis, pallor, jaundice (hemolytic due to ineffective erythropoiesis).

Investigations:

Serum B12: Low (<200 pg/mL)
Elevated serum methylmalonic acid and homocysteine (most sensitive markers)
CBC: Macrocytic anemia, hypersegmented neutrophils
MRI spine: T2 hyperintensity in posterior and lateral columns ("inverted V sign")

Treatment: IM Hydroxocobalamin 1 mg daily for 7 days, then weekly for 4 weeks, then monthly lifelong (if pernicious anemia or malabsorption).

f) Tropical Sprue

Definition: Chronic malabsorptive disorder occurring in tropical regions (South/Southeast Asia, Caribbean, Central America), affecting the small intestine.

Etiology: Likely infectious - possibly toxigenic bacteria (E. coli, Klebsiella) causing persistent colonization of small bowel; vitamin B12 and folate deficiency contribute to mucosal damage.

Pathology: Villous atrophy and crypt hyperplasia of small intestinal mucosa (similar to celiac disease but not immune-mediated).

Clinical Features:

Chronic profuse watery/steatorrhea (fat malabsorption)
Weight loss, anorexia
Abdominal distension and cramps
Glossitis, stomatitis, angular cheilitis (B12/folate deficiency)
Megaloblastic anemia (B12 and folate deficiency)
Peripheral edema (hypoalbuminemia)
Night blindness (vitamin A deficiency)
Bone pain (vitamin D deficiency)

Investigations:

Stool for fat: Steatorrhea (Sudan stain positive)
D-xylose absorption test: Abnormal (small bowel absorption defect)
Jejunal biopsy: Partial villous atrophy, crypt hyperplasia
Serum B12, folate: Low
CBC: Macrocytic anemia

Treatment:

Tetracycline 250 mg QID for 3-6 months (mainstay)
Folic acid 5 mg/day (often leads to early improvement)
Vitamin B12 IM injections if deficient
Nutritional support; avoid risk factors

Q.8 Write Short Notes

a) Informed Consent

Definition: A process by which a patient voluntarily authorizes a healthcare provider to perform a medical intervention, after receiving and understanding relevant information.

Legal Basis: Rooted in the ethical principle of autonomy and patient's right to self-determination. Violation = battery/assault in law.

Essential Elements (VALID CONSENT must include):

Disclosure: Physician must provide:
- Nature of the condition/diagnosis
- Proposed treatment/procedure
- Material risks and benefits
- Alternatives (including no treatment)
- Expected outcomes
Comprehension: Patient must understand the information (in their language; interpreter if needed)
Voluntariness: Decision free from coercion, undue influence, or duress
Competence/Capacity: Patient must be mentally competent (adults; >18 years; no cognitive impairment)

Types:

Express: Written (for major procedures) or oral
Implied: Assumed in emergencies or routine physical examination
Proxy consent: By guardian/parent for minors or incompetent patients

Exceptions (consent not required):

Life-threatening emergencies
Communicable disease treatment (public health law)
Court-ordered treatment

Special Situations:

Minors: Parent/guardian consent; but mature minors may consent for certain conditions (contraception, STIs)
Mentally ill: Advance directive honored; else next-of-kin or court
Research: Full informed written consent mandatory (Helsinki Declaration)

Documentation: Written consent form, signed by patient, physician, and witness; filed in medical record.

b) Complications of Diabetes Mellitus

A) Acute Complications:

Diabetic Ketoacidosis (DKA): Type 1 DM; insulin deficiency + counter-regulatory hormones → ketone body production → anion gap metabolic acidosis; Kussmaul breathing, vomiting, fruity breath
Hyperosmolar Hyperglycemic State (HHS): Type 2 DM; severe hyperglycemia (>600 mg/dL), hyperosmolarity, dehydration, without significant ketosis
Hypoglycemia: Insulin excess; sweating, tremors, confusion, seizures; treat with 15g glucose orally or IV dextrose

B) Chronic Complications:

Microvascular (due to hyperglycemia + glycation of basement membrane):

Complication	Features
Diabetic Nephropathy	Microalbuminuria → proteinuria → nephrotic syndrome → ESRD; Kimmelstiel-Wilson nodules on biopsy
Diabetic Retinopathy	NPDR (microaneurysms, hard exudates, flame hemorrhages) → PDR (neovascularization, vitreous hemorrhage, retinal detachment); leading cause of blindness in working-age adults
Diabetic Neuropathy	Distal symmetric sensorimotor polyneuropathy (most common); autonomic neuropathy (gastroparesis, orthostatic hypotension, ED, diabetic bladder); mononeuropathy

Macrovascular (due to accelerated atherosclerosis):

CAD / MI (2-4x increased risk) - leading cause of death
Stroke (2x increased risk)
Peripheral arterial disease (PAD): Claudication, gangrene, diabetic foot

Other:

Diabetic foot: Neuropathy + PAD + infection → ulceration → osteomyelitis → amputation
Infections: Recurrent UTI, candidiasis, mucormycosis, malignant otitis externa
Skin: Acanthosis nigricans, necrobiosis lipoidica, diabetic dermopathy

c) CREST Syndrome

Definition: CREST is the limited cutaneous form of Systemic Sclerosis (Scleroderma), characterized by:

C - Calcinosis (calcium deposits in skin, periarticular tissues)
R - Raynaud's phenomenon (episodic vasospasm of digits: white→blue→red on cold exposure)
E - Esophageal dysmotility (dysphagia; lower esophageal hypomotility → reflux)
S - Sclerodactyly (skin thickening/tightening limited to fingers/distal extremities)
T - Telangiectasias (dilated capillaries on skin, face, mucous membranes)

Compared to Diffuse SSc: CREST involves skin distal to elbows/knees only; slower progression; better prognosis; but still has significant visceral involvement.

Immunology:

Anti-centromere antibodies (ACA) - highly specific for CREST (70-80% positive)
ANA positive in >90%

Complications:

Pulmonary arterial hypertension (PAH) - major cause of death in CREST
Primary biliary cirrhosis (PBC) - associated
Malabsorption (small bowel involvement)
Scleroderma renal crisis (less common than in diffuse SSc)

Treatment (no cure - symptomatic):

Raynaud's: Calcium channel blockers (nifedipine), prostanoids (iloprost)
GERD: PPIs
PAH: Bosentan, sildenafil, epoprostenol
Calcinosis: No highly effective treatment; colchicine
Skin: Moisturizers, physiotherapy
Immunosuppressants: Methotrexate, MMF for skin/lung involvement

d) Anemia Due to Gastrointestinal Bleeding

Mechanism: Blood loss from GI tract → iron loss (as hemoglobin) → iron deficiency → reduced hemoglobin synthesis → microcytic hypochromic anemia.

Sources of GI Blood Loss:

Upper GI (above Treitz ligament):

Peptic ulcer disease (most common cause of upper GIB)
Esophageal/gastric varices (portal hypertension)
Mallory-Weiss tear
Esophagitis, gastric erosions (NSAIDs, H. pylori)
Gastric/esophageal carcinoma

Lower GI:

Colorectal carcinoma (most important cause of iron deficiency anemia in elderly)
Hemorrhoids, anal fissure
Inflammatory bowel disease (Crohn's, UC)
Angiodysplasia
Diverticular disease
Polyps

Types of Presentation:

Hematemesis/melena: Upper GIB
Hematochezia: Lower GIB (or massive upper GIB)
Occult blood loss: Silent chronic bleeding (common with colorectal cancer) → slowly progressive iron deficiency

Clinical Features of Iron Deficiency Anemia:

Fatigue, pallor, dyspnea on exertion, palpitations
Koilonychia (spoon-shaped nails), brittle hair and nails
Angular stomatitis, glossitis, pharyngeal web (Plummer-Vinson syndrome)
Pica (craving for non-food substances)

Investigations:

CBC: Low Hb, low MCV (<80 fL), low MCH, high RDW
Blood film: Microcytic hypochromic cells, pencil cells (elliptocytes), anisocytosis/poikilocytosis
Serum iron: Low; TIBC: High; Transferrin saturation: <16%; Serum ferritin: Low (<12 ng/mL) - most sensitive marker
Fecal occult blood test (FOBT) / fecal calprotectin
Endoscopy (OGD/colonoscopy) to identify source - mandatory in GI blood loss anemia

Management:

Treat the underlying cause (endoscopic hemostasis, surgery, proton pump inhibitors, H. pylori eradication)
Iron replacement: Oral ferrous sulfate 200 mg TID x 3-6 months (replenish stores); IV iron sucrose/ferric carboxymaltose if intolerant or severe
Reticulocyte rise expected in 1 week; Hb rise 1-2 g/dL per month
Blood transfusion for Hb <7 g/dL or symptomatic

These answers are based on Harrison's Principles of Internal Medicine, Goldman-Cecil Medicine, Adams and Victor's Neurology, and other authoritative textbook sources in the medical library.

This is a shared conversation. Sign in to Orris to start your own chat.